Literature DB >> 7789877

Fertility therapy in the setting of a history of invasive epithelial ovarian cancer.

C A Bandera1, D W Cramer, A J Friedman, E E Sheets.   

Abstract

A link between fertility drugs and epithelial ovarian cancer has been suggested by at least one case-control study, and by multiple case reports of such tumors developing following fertility drug therapy. We report the case of a woman with stage IC grade 1 mucinous epithelial ovarian cancer who died of recurrent disease shortly after receiving gonadotropin therapy for ovulation induction. The patient was initially treated with a staging procedure, unilateral salpingo-oophorectomy, and 3 courses of cytoxan and carboplatinum. Over the next 3 years she underwent 2 cycles of ovulation induction with exogenous gonadotropins. Five months after the second cycle, the patient presented with a bowel obstruction and extensive recurrence of disease. Two months later she died despite extensive surgical debulking, and cis-platinum and Taxol chemotherapy. Although a causal relationship between fertility therapy and ovarian cancer has not been established, this case report suggests ovulation induction may be inadvisable in a woman with a prior diagnosis of invasive epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789877     DOI: 10.1006/gyno.1995.1193

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  2 in total

1.  Effects of antisense oligodeoxynucleotide to follicle-stimulating hormone receptor on the cell proliferation and apoptosis in cells derived from human ovarian mucinous cystadenocarcinoma in Vitro.

Authors:  Shuang Li; Ding Ma; Changhong Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-02

2.  Assessment of cells in the ascitic fluid of women with ovarian hyperstimulation syndrome: the clinical implications for subsequent ovarian malignancy.

Authors:  Ioannis Hatzipetros; Peter M Gocze; Katalin Cziraky; Kalman Kovacs; Endre Kalman; Balint Farkas
Journal:  Reprod Biol Endocrinol       Date:  2013-09-12       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.